+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID07731789

Evaluating Tafasitamab and Rituximab Combination Therapy for Newly Diagnosed Follicular Lymphoma Patients

Led by University of Washington · Updated on 2026-10-15

30

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of tafasitamab and rituximab as a treatment for newly diagnosed follicular lymphoma, a type of cancer affecting B cells. This phase II trial aims to understand how well these two monoclonal antibodies work together in treating this condition by targeting specific proteins on cancer cells to help the immune system attack them. Participants receive rituximab and tafasitamab intravenously in cycles lasting 28 days. During cycles 1 to 3, rituximab is given on day 1, and tafasitamab is given on days 1, 8, 15, and 22. In cycles 4 to 6, rituximab is administered on day 1, and tafasitamab on days 1 and 15. After these cycles, disease response is assessed those with a complete response enter active monitoring, while others receive cycles 7 to 12, receiving tafasitamab on days 1 and 15. Treatment continues if there is no disease progression or unacceptable toxicity. Throughout the study, participants undergo PET and CT scans, bone marrow biopsies and aspirations, and blood sample collections to monitor disease and safety. After completing treatment, participants are followed for up to five years with periodic evaluations. The primary outcome is the rate of complete remission within one year of starting treatment, along with assessments of response, survival, and adverse events.

CONDITIONS

Brief Title

Tafasitamab and Rituximab for the Treatment of Newly Diagnosed Follicular Lymphoma

Research Team

M

Mengyang Di, MD, PhD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here